Table 1.
Antisense oligos of the training set
| Oligo name | Target site position | Target sequence (5′→3′) | Inhibition (%) | Disruption energy (kcal/mol) | No. of test runs* |
|---|---|---|---|---|---|
| KM726 | 277–296 | AAACCCUGGCGUUACCCAAC | 89.7 ± 11.8 | −7.075 | 19 |
| KM1227 | 243–262 | CACUGGCCGUCGUUUUACAA | 59.1 ± 9.4 | −13.727 | 4 |
| KM1228 | 306–325 | UUGCAGCACAUCCCCCUUUC | 59.8 ± 10.5 | −7.009 | 4 |
| KM728 | 733–752 | UGAAUUUGACCUGAGCGCAU | 40.1 ± 15.6 | −10.3 | 12 |
| KM729 | 836–855 | CGGAUGAGCGGCAUUUUCCG | 48.9 ± 14.4 | −14.065 | 10 |
| KM730 | 1133–1152 | GCCGAAAUCCCGAAUCUCUA | 50.4 ± 12.4 | −8.065 | 8 |
| KM731 | 1357–1376 | GCUGAUGAAGCAGAACAACU | 27.0 ± 17.1 | −9.892 | 3 |
| KM734 | 2399–2418 | AACCUCAGUGUGACGCUCCC | 37.0 ± 9.2 | −7.495 | 3 |
| KM1110 | 514–533 | UGCGCCCAUCUACACCAACG | 39.4 ± 11.5 | −5.045 | 3 |
| KM1111 | 1468–1487 | UAUUGAAACCCACGGCAUGG | 53.4 ± 11.9 | −8.721 | 8 |
| KM1112 | 2262–2281 | UGAUUGAACUGCCUGAACUA | 58.8 ± 14.4 | −5.226 | 8 |
| KM1165 | 2928–2947 | GGCCGCAAGAAAACUAUCCC | 66.8 ± 7.8 | −11.258 | 2 |
| KM1159 | 322–341 | UUUCGCCAGCUGGCGUAAUA | 59.8 ± 4.2 | −6.953 | 2 |
| KM1160 | 674–693 | UUUCAUCUGUGGUGCAACGG | 60.2 ± 10.1 | −5.461 | 2 |
| KM1161 | 1299–1318 | AGCAUCAUCCUCUGCAUGGU | 39.8 ± 18.5 | −21.914 | 4 |
| KM1162 | 1818–1837 | GCCCGCUGAUCCUUUGCGAA | 53.4 ± 12.5 | −9.671 | 4 |
| KM1163 | 2793–2812 | ACCGGAUUGAUGGUAGUGGU | 23.1 ± 20.7 | −23.258 | 5 |
| KM1164 | 2818–2837 | GGCGAUUACCGUUGAUGUUG | 39.8 ± 15.0 | −15.113 | 4 |
*Number of independent tests performed. Each run of the test was done with triplicate samples. For KM726, KM728, KM729, KM730, KM111 and KM1112, inhibition data here include early runs presented in Figure 1 and additional runs after the Western blot analysis. For each run, an average inhibition percentage was computed for the triplicate samples. The standard error was calculated using data from multiple runs.